Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
Regenxbio: Better Investment Case Than Adverum
08:00am, Wednesday, 12'th May 2021
Regenxbio: Better Investment Case Than Adverum
REGENXBIO to Present at Upcoming Investor Conferences
04:05pm, Thursday, 06'th May 2021
ROCKVILLE, Md., May 6, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the following May investor conferences, which will each be held in a virtual meeting form
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates
03:01am, Thursday, 06'th May 2021
Regenxbio (RGNX) delivered earnings and revenue surprises of -6.19% and -32.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
REGENXBIO Inc. (RGNX) CEO Ken Mills on Q1 2021 Results - Earnings Call Transcript
09:44pm, Wednesday, 05'th May 2021
REGENXBIO Inc. (RGNX) CEO Ken Mills on Q1 2021 Results - Earnings Call Transcript
REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights
04:05pm, Wednesday, 28'th Apr 2021
ROCKVILLE, Md., April 28, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 5, 2021, at 4:30 p.m.
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting
04:55pm, Tuesday, 27'th Apr 2021
ROCKVILLE, Md., April 27, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that four oral and nine poster presentations will be presented at the American Society of Gene and Cell Th
REGENXBIO To Present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit
07:05am, Wednesday, 21'st Apr 2021
ROCKVILLE, Md., April 21, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran M.
REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome)
04:14pm, Wednesday, 14'th Apr 2021
ROCKVILLE, Md., April 14, 2021 /PRNewswire/ -- First patient dosed at third dose level in ongoing trial of RGX-121, a one-time gene therapy for MPS II; total of nine patients have been dosed at four l
New Strong Sell Stocks for March 24th
10:42am, Wednesday, 24'th Mar 2021
IHG, NNN, PRMW, RGNX, and WW have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2021
REGENXBIO, Inc. (RGNX) CEO Ken Mills on Q4 2020 Results - Earnings Call Transcript
10:05pm, Monday, 01'st Mar 2021
REGENXBIO, Inc. (RGNX) CEO Ken Mills on Q4 2020 Results - Earnings Call Transcript
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
06:12pm, Monday, 01'st Mar 2021
Regenxbio (RGNX) delivered earnings and revenue surprises of -211.71% and -83.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Week 7 MDA Breakout Stocks - February 2021: Short-Term Picks To Give You An Edge
07:26am, Sunday, 14'th Feb 2021
Week 7 MDA Breakout Stocks - February 2021: Short-Term Picks To Give You An Edge
ROCKVILLE, Md., Feb. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that additional positive interim data from a total of eight patients in Cohorts 1 and 2 of the ongoing Phase
REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference
07:05am, Friday, 05'th Feb 2021
ROCKVILLE, Md., Feb. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that two oral presentations will be presented at the Angiogenesis, Exudation, and Degeneration 2021 conferenc
REGENXBIO Announces Presentations at the 17th Annual WORLDSymposium™ 2021
07:05am, Monday, 01'st Feb 2021
ROCKVILLE, Md., Feb. 1, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and nine poster presentations will be presented at the 17th Annual WORLDSymposium™, taking
